CXChaofeng Xing

Chaofeng Xing

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Chaofeng Xing has a total of 10 co-authors. Here are the top co-authors by number of shared publications:

  • Allan Zijian Zhao

    The Eighth Affiliated Hospital, Southern Medical University (The First People’s Hospital of Shunde, Foshan), China

    1 shared publication
  • Fanghong Li

    The International Translational Medical Research Center, Guangdong Engineering Technology Research Center of Metabolic Disorders Interdisciplinary Precision Prevention and Digital Healthcare The Eighth Affiliated Hospital, Southern Medical University Foshan China

    1 shared publication
  • Jinlin Du

    School of public health, Guangdong Medical University, Dongguan, Guangdong, China

    1 shared publication
  • Qihua Xu

    The school of Biomedical and Pharmaceutical sciences, Guangdong University of Technology, Guangzhou 510006, China

    1 shared publication
  • Su-Mei Cao

    Department of Cancer Prevention, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China

    1 shared publication
  • Sujin Zhou

    The School of Biomedical and Pharmaceutical Sciences Guangdong University of Technology Guangzhou China

    1 shared publication

Latest Publications

  • Open Access

    Adiponectin Suppresses Metastasis of Nasopharyngeal Carcinoma through Blocking the Activation of NF-κB and STAT3 Signaling

    by Zongmeng Zhang, Jinlin Du, Qihua Xu, Chaofeng Xing, Yuyu Li, Sujin Zhou, Zhenggang Zhao, Yunping Mu, Zijian (Allan) Zhao, Sumei Cao, et al.

    Adiponectin is an adipocytokine with anti-inflammatory and anticancer properties. Our previous study has shown that blood adiponectin levels were inversely correlated to the risk of nasopharyngeal carcinoma (NPC), and that adiponectin could directly suppress the proliferation of NPC cells. However, the effect of adiponectin on NPC metastasis remains unknown. Here, we revealed in clinical studies that serum adiponectin level was inversely correlated with tumor stage, recurrence, and metastasis in NPC patients, and that low serum adiponectin level also correlates with poor metastasis-free survival. Coculture with recombinant adiponectin suppressed the migration and invasion of NPC cells as well as epithelial–mesenchymal transition (EMT). In addition, recombinant adiponectin dampened the activation of NF-κB and STAT3 signaling pathways induced by adipocyte-derived proinflammatory factors such as leptin, IL-6, and TNF-α. Pharmacological activation of adiponectin receptor through its specific agonist, AdipoRon, largely stalled the metastasis of NPC cells. Taken together, these findings demonstrated that adiponectin could not only regulate metabolism and inhibit cancer growth, but also suppress the metastasis of NPC. Pharmacological activation of adiponectin receptor may be a promising therapeutic strategy to stall NPC metastasis and extend patients’ survival.